• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术前 CA125 作为超声引导高强度聚焦超声消融术后子宫腺肌病症状复发的危险因素。

Preoperative CA125 as a risk factor for symptom recurrence of adenomyosis after ultrasound-guided high-intensity focused ultrasound ablation surgery.

机构信息

State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China.

Department of Obstetrics and Gynecology, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, China.

出版信息

Int J Hyperthermia. 2022;39(1):1164-1169. doi: 10.1080/02656736.2022.2107716.

DOI:10.1080/02656736.2022.2107716
PMID:36075579
Abstract

OBJECTIVES

To investigate the relationship between preoperative CA125 and symptom recurrence in adenomyosis after ultrasound-guided high-intensity focused ultrasound ablation surgery (FUAS).

METHODS

A total of 502 adenomyosis patients after FUAS in Affiliated Nanchong Central Hospital of North Sichuan Medical College from June 2017 to March 2021 were reviewed. Factors associated with symptom recurrence of adenomyosis were analyzed by binary logistic regression model. ROC was used to determine the optimal cutpoint. Magnitude of preoperative CA125 relating to timing of symptom recurrence was measured by cox regression and Kaplan-Meier (K-M) curves. Besides, multiple liner regression model was used to identify the impacting factors for preoperative CA125.

RESULTS

Multiple binary logistic analysis showed preoperative CA125 was related to symptom recurrence (OR = 1.002, 95%: 1.000~1.004,  = 0.043). The ROC of preoperative CA125 for recurrence validated 35 U/ml had a high sensitivity (82.5%). Preoperative CA125 was related to timing of symptom recurrence (HR = 2.255, 95%: 1.387-3.667,  = 0.001). K-M curves showed medium recurrence time in preoperative CA125 level >35 U/ml group (38.5 months) was shorter than that in CA125 level ≤35 U/ml group (44.5 months) ( = 0.001). Multiple liner regression analyses showed uterus volume and adenomyotic lesions volume positively correlated to preoperative CA125 level, while age negatively correlated to preoperative CA125 level.

CONCLUSION

The higher level of preoperative CA125 was related to an earlier onset of symptom recurrence after FUAS.

摘要

目的

探讨超声引导高强度聚焦超声消融术(FUAS)治疗后子宫腺肌病患者术前 CA125 与症状复发的关系。

方法

回顾性分析 2017 年 6 月至 2021 年 3 月川北医学院附属医院接受 FUAS 治疗的 502 例子宫腺肌病患者的临床资料,采用二项 logistic 回归模型分析与子宫腺肌病症状复发相关的因素,采用 ROC 确定最佳截断值。采用 cox 回归和 Kaplan-Meier(K-M)曲线分析术前 CA125 与症状复发时间的关系,采用多元线性回归模型分析术前 CA125 的影响因素。

结果

多因素二项 logistic 分析显示,术前 CA125 与症状复发有关(OR=1.002,95%CI:1.000~1.004, = 0.043)。术前 CA125 对复发的 ROC 验证 35 U/ml 具有较高的灵敏度(82.5%)。术前 CA125 与症状复发时间有关(HR=2.255,95%CI:1.387~3.667, = 0.001)。K-M 曲线显示,术前 CA125 水平>35 U/ml 组的中位复发时间(38.5 个月)短于 CA125 水平≤35 U/ml 组(44.5 个月)( = 0.001)。多元线性回归分析显示,子宫体积和腺肌瘤体积与术前 CA125 水平呈正相关,而年龄与术前 CA125 水平呈负相关。

结论

术前 CA125 水平越高,FUAS 后症状复发的时间越早。

相似文献

1
Preoperative CA125 as a risk factor for symptom recurrence of adenomyosis after ultrasound-guided high-intensity focused ultrasound ablation surgery.术前 CA125 作为超声引导高强度聚焦超声消融术后子宫腺肌病症状复发的危险因素。
Int J Hyperthermia. 2022;39(1):1164-1169. doi: 10.1080/02656736.2022.2107716.
2
Magnetic Resonance Imaging-Based Classification Systems for Informing Better Outcomes of Adenomyosis After Ultrasound-Guided High-Intensity Focused Ultrasound Ablating Surgery.基于磁共振成像的分类系统可提高超声引导高强度聚焦超声消融术后子宫腺肌病的疗效。
J Magn Reson Imaging. 2024 May;59(5):1787-1797. doi: 10.1002/jmri.28943. Epub 2023 Sep 6.
3
Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study.促性腺激素释放激素激动剂联合高强度聚焦超声消融治疗子宫腺肌病的临床研究。
BJOG. 2017 Aug;124 Suppl 3:7-11. doi: 10.1111/1471-0528.14736.
4
[Clinical efficacy of focused ultrasound ablation surgery in the treatment of internal adenomyosis].聚焦超声消融手术治疗内在型子宫腺肌病的临床疗效
Zhonghua Fu Chan Ke Za Zhi. 2022 Apr 25;57(4):259-264. doi: 10.3760/cma.j.cn112141-20210915-00521.
5
Serum CA125 as a biomarker for dysmenorrhea in adenomyosis.血清 CA125 作为子宫腺肌病痛经的生物标志物。
Int J Gynaecol Obstet. 2023 Oct;163(1):131-139. doi: 10.1002/ijgo.14832. Epub 2023 May 12.
6
Analysis of related factors influencing postoperative recurrence of adenomyosis treated with HIFU.高强度聚焦超声治疗子宫腺肌病术后复发相关因素分析
Arch Gynecol Obstet. 2024 May;309(5):1765-1773. doi: 10.1007/s00404-023-07340-x. Epub 2024 Feb 12.
7
Effective ablation therapy of adenomyosis with ultrasound-guided high-intensity focused ultrasound.超声引导高强度聚焦超声治疗子宫腺肌病的疗效。
Int J Gynaecol Obstet. 2014 Mar;124(3):207-11. doi: 10.1016/j.ijgo.2013.08.022. Epub 2013 Dec 4.
8
[Pregnancy outcomes and symptom improvement of patients with adenomyosis treated with high intensity focused ultrasound ablation].高强度聚焦超声消融治疗子宫腺肌病患者的妊娠结局及症状改善情况
Zhonghua Fu Chan Ke Za Zhi. 2016 Nov 25;51(11):845-849. doi: 10.3760/cma.j.issn.0529-567X.2016.11.009.
9
Transcervical Ultrasound-guided Radiofrequency Ablation of Adenomyosis: A Case Report.经阴道超声引导下子宫腺肌病射频消融治疗:病例报告。
J Minim Invasive Gynecol. 2023 Jun;30(6):502-507. doi: 10.1016/j.jmig.2023.02.018. Epub 2023 Mar 4.
10
Safety and Efficacy of Ultrasound-Guided High-Intensity Focused Ultrasound Treatment for Uterine Fibroids and Adenomyosis.超声引导高强度聚焦超声治疗子宫肌瘤和子宫腺肌病的安全性和有效性。
Ultrasound Med Biol. 2019 Dec;45(12):3214-3221. doi: 10.1016/j.ultrasmedbio.2019.08.022. Epub 2019 Sep 25.

引用本文的文献

1
Progress in High Intensity Focused Ultrasound Ablation for Fertility Preservation Therapy of Uterine Fibroids and Adenomyosis.高强度聚焦超声消融术在子宫肌瘤和子宫腺肌病生育保留治疗中的进展
Reprod Sci. 2025 Jan;32(1):15-25. doi: 10.1007/s43032-024-01745-y. Epub 2024 Nov 12.
2
CA125-Associated Activated Partial Thromboplastin Time and Thrombin Time Decrease in Patients with Adenomyosis.子宫腺肌病患者中CA125相关的活化部分凝血活酶时间及凝血酶时间降低
J Multidiscip Healthc. 2024 Jan 16;17:251-261. doi: 10.2147/JMDH.S435365. eCollection 2024.